The Power Of New Weight-Loss Drugs

GLP-1s offer far more across the healthcare sector than just weight-loss, with far-reaching societal implications, explains T. Rowe Price's Nabil Hanano

Related Keywords

United States ,Americans ,Novo Nordisk Rybelsus ,Eli Lilly ,Nabil Hanano ,Novo Nordisk ,Associate Portfolio Manager ,Global Growth Equities ,